52% of innovations approved in 2020 have some limitation in their prescription or dispensing

HomeNews & Events

52% of innovations approved in 2020 have some limitation in their prescription or dispensing

El 52% de las innovaciones aprobadas en 2020 tienen alguna limitación a la prescripción o la dispensación

Omakase2021-02-10T12:16:21+00:00February 10th, 2021|News & Events|

We are proud to announce the release of Horizon Scanning 2020 where Omakase Consulting is working with Orphar-SEFH

We are proud to announce the release of Horizon Scanning 2020 where Omakase Consulting is working with Orphar-SEFH

February 23rd, 2021 | 0 Comments
CHMP positive opinions January 2021

CHMP positive opinions January 2021

February 2nd, 2021 | 0 Comments
Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.

Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.

December 23rd, 2020 | 0 Comments
It has been a pleasure to coordinate, together with Zogenix, a project directed to provide information, training and contribute to empowerment of patients suffering from Dravet Syndrome and their caregivers

It has been a pleasure to coordinate, together with Zogenix, a project directed to provide information, training and contribute to empowerment of patients suffering from Dravet Syndrome and their caregivers

December 21st, 2020 | 0 Comments
300 experts across country and regions claim to create a new HispaNice to assess innovative drugs in the Spanish NHS

300 experts across country and regions claim to create a new HispaNice to assess innovative drugs in the Spanish NHS

December 14th, 2020 | 0 Comments
Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated

Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated

November 17th, 2020 | 0 Comments
The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website

The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website

November 16th, 2020 | 0 Comments
Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.

Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.

November 13th, 2020 | 0 Comments

52% of innovations approved in 2020 have some limitation in their prescription or dispensing

52% of innovations approved in 2020 have some limitation in their prescription or dispensing

Share This Article

Related Posts

Leave A Comment Cancel reply